Nafamostat Efficacy in Phase 3 Registrational CRRT Study

Status: RECRUITING

Eligibility Criteria

Sex: ALL
Age: 18 years to 80 years old
Healthy Volunteers: This study is NOT accepting healthy volunteers
Inclusion Criteria:

- Patients requiring CRRT or undergoing CRRT initiated within the prior 48 hours
- Patients who cannot tolerate heparin or are at high risk of bleeding

Exclusion Criteria:

- Patients weighing less than 50 kg
- Patients receiving systemic anticoagulation
- Patients with active bleeding

Conditions & Interventions

Interventions:
DEVICE: Niyad (nafamostat mesylate), DEVICE: Placebo (0.9% NaCl)
Conditions:
Acute Kidney Injury
Keywords:
continuous renal replacement therapy, anticoagulation

More Information

Description:
A prospective, randomized, placebo-controlled clinical study to investigate the safety and efficacy of Niyad (nafamostat mesylate) for anticoagulation of extracorporeal blood circulating through a dialysis filter in patients undergoing CRRT who cannot tolerate heparin or are at higher risk for bleeding.

Contact(s): Ilham Ilham Boutahri - Ilham.Boutahri@cchmc.org
Principal Investigator:
Principal Investigator ID:
Phase: NA
IRB Number:
System ID: NCT06150742